JP2024506279A5 - - Google Patents
Info
- Publication number
- JP2024506279A5 JP2024506279A5 JP2023546322A JP2023546322A JP2024506279A5 JP 2024506279 A5 JP2024506279 A5 JP 2024506279A5 JP 2023546322 A JP2023546322 A JP 2023546322A JP 2023546322 A JP2023546322 A JP 2023546322A JP 2024506279 A5 JP2024506279 A5 JP 2024506279A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- cell
- iii
- aav
- producer cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163148350P | 2021-02-11 | 2021-02-11 | |
| US63/148,350 | 2021-02-11 | ||
| PCT/US2022/015975 WO2022173944A1 (en) | 2021-02-11 | 2022-02-10 | Adeno-associated virus (aav) production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024506279A JP2024506279A (ja) | 2024-02-13 |
| JP2024506279A5 true JP2024506279A5 (enExample) | 2025-02-14 |
Family
ID=80448907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023546322A Pending JP2024506279A (ja) | 2021-02-11 | 2022-02-10 | アデノ随伴ウイルス（ａａｖ）産生 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220259572A1 (enExample) |
| EP (1) | EP4291665A1 (enExample) |
| JP (1) | JP2024506279A (enExample) |
| KR (1) | KR20230142712A (enExample) |
| CN (1) | CN116917490A (enExample) |
| CA (1) | CA3206771A1 (enExample) |
| IL (1) | IL304688A (enExample) |
| WO (1) | WO2022173944A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR127674A1 (es) | 2021-10-18 | 2024-02-21 | Regeneron Pharma | Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios |
| JP2024537896A (ja) | 2021-10-18 | 2024-10-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞 |
| EP4578943A4 (en) * | 2022-08-25 | 2026-02-25 | Fujifilm Corp | PROCESS FOR TARGETING VIRUS PRODUCTION AND CULTURE COMPOSITION |
| JP2025534369A (ja) | 2022-09-30 | 2025-10-15 | ポリプラス トランスフェクション | ３種の異なるヘルパーウイルス由来のヘルパーエレメントを含むキメラヘルパー核酸分子 |
| KR20260082361A (ko) | 2023-08-31 | 2026-06-04 | 디노 테라퓨틱스, 인코포레이티드 | 캡시드 폴리펩타이드 및 이의 사용 방법 |
| CN121780618A (zh) * | 2023-12-13 | 2026-04-03 | 广州派真生物技术有限公司 | 一种高产重组腺相关病毒的辅助质粒及应用 |
| TW202545971A (zh) | 2024-02-08 | 2025-12-01 | 美商戴諾治療公司 | 殼體多肽及其使用方法 |
| AU2025218748A1 (en) | 2024-02-09 | 2026-08-06 | F. Hoffmann-La Roche Ag | Method for producing recombinant adeno-associated viral particles |
| WO2025252480A1 (en) | 2024-06-07 | 2025-12-11 | F. Hoffmann-La Roche Ag | Method for purifying plasmid dna |
| US20260022401A1 (en) | 2024-07-22 | 2026-01-22 | Hoffmann-La Roche Inc. | Novel AAV rep ORFs and Rep polypeptides |
| WO2026037757A1 (en) | 2024-08-13 | 2026-02-19 | F. Hoffmann-La Roche Ag | Modified aav particles |
| WO2026064428A2 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026064444A1 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026064442A2 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026112397A1 (en) | 2024-11-22 | 2026-05-28 | Biogen Ma Inc. | Compositions and methods for adeno-associated virus production |
| WO2026122963A1 (en) | 2024-12-06 | 2026-06-11 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026132012A1 (en) | 2024-12-20 | 2026-06-25 | F. Hoffmann-La Roche Ag | Aav particle processing using affinity chromatography with gradient elution |
| WO2026132139A1 (en) | 2024-12-20 | 2026-06-25 | F. Hoffmann-La Roche Ag | Purification process for viral vectors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE286138T1 (de) * | 1998-03-20 | 2005-01-15 | Univ Pennsylvania | Zusammensetzungen und verfahren zur helfer-freien herstellung von rekombinante adeno-assoziierten viren |
| EP3219313B1 (en) * | 2011-04-18 | 2020-10-28 | National Center of Neurology and Psychiatry | Drug delivery particle and method for producing the same |
-
2022
- 2022-02-10 EP EP22706191.8A patent/EP4291665A1/en active Pending
- 2022-02-10 CN CN202280012757.5A patent/CN116917490A/zh active Pending
- 2022-02-10 US US17/669,033 patent/US20220259572A1/en active Pending
- 2022-02-10 KR KR1020237025723A patent/KR20230142712A/ko active Pending
- 2022-02-10 JP JP2023546322A patent/JP2024506279A/ja active Pending
- 2022-02-10 CA CA3206771A patent/CA3206771A1/en active Pending
- 2022-02-10 WO PCT/US2022/015975 patent/WO2022173944A1/en not_active Ceased
-
2023
- 2023-07-24 IL IL304688A patent/IL304688A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guan et al. | The genome of human parvovirus b19 can replicate in nonpermissive cells with the help of adenovirus genes and produces infectious virus | |
| Buck et al. | Efficient intracellular assembly of papillomaviral vectors | |
| ES2552688T3 (es) | Adenovirus de simio con proteínas de la cápside hexónica de SAdV-46 y usos del mismo | |
| US6258595B1 (en) | Compositions and methods for helper-free production of recombinant adeno-associated viruses | |
| US20030092161A1 (en) | Compositions and methods for production of recombinant viruses, and uses therefor | |
| Wu et al. | Overexpression of Ad5 precursor terminal protein accelerates recombinant adenovirus packaging and amplification in HEK-293 packaging cells | |
| AU2409200A (en) | Compositions and methods useful for production of recombinant viruses which require helper viruses | |
| EP4200316B1 (en) | Process for making a recombinant aav library | |
| Guimet et al. | The adenovirus L4-22K protein has distinct functions in the posttranscriptional regulation of gene expression and encapsidation of the viral genome | |
| JP2024508463A (ja) | 組換えａａｖベクターの製造及び使用 | |
| Duffy et al. | Purification of adenovirus and adeno-associated virus: comparison of novel membrane-based technology to conventional techniques | |
| Nagy et al. | Engineered CHO cells as a novel AAV production platform for gene therapy delivery | |
| WO2023053899A1 (ja) | ウイルスベクター産生誘導剤 | |
| US20220242917A1 (en) | Compositions and methods for producing adeno-associated viral vectors | |
| Gonçalves et al. | Targeted chromosomal insertion of large DNA into the human genome by a fiber-modified high-capacity adenovirus-based vector system | |
| JP7834758B2 (ja) | 低レベルのｖａ－ｒｎａを有する産生細胞 | |
| CN118291541B (zh) | 一种诱导型启动子 | |
| JP2023546116A5 (enExample) | ||
| Li et al. | A novel Ad5/11 chimeric oncolytic adenovirus for improved glioma therapy | |
| El-Andaloussi et al. | Novel adenovirus-based helper system to support production of recombinant parvovirus | |
| Glauser et al. | Four-dimensional visualization of the simultaneous activity of alternative adeno-associated virus replication origins | |
| JP2024073540A (ja) | Ｒａｂエスコートタンパク質の力価アッセイ | |
| Nagano et al. | An efficient construction of conditionally replicating adenoviruses that target tumor cells with multiple factors | |
| JP2009077737A5 (enExample) | ||
| JP2022545534A (ja) | ヒト血液脳関門を通過するためのアデノ随伴ウイルスベクター |